Lu Dunyue, Qu Changsheng, Goussev Anton, Jiang Hao, Lu Chang, Schallert Timothy, Mahmood Asim, Chen Jieli, Li Yi, Chopp Michael
Department of Neurosurgery, Henry Ford Health System, Detroit, Michigan 48202, USA.
J Neurotrauma. 2007 Jul;24(7):1132-46. doi: 10.1089/neu.2007.0288.
Traumatic brain injury (TBI) remains a major public health problem globally. Presently, there is no way to restore cognitive deficits caused by TBI. In this study, we seek to evaluate the effect of statins (simvastatin and atorvastatin) on the spatial learning and neurogenesis in rats subjected to controlled cortical impact. Rats were treated with atorvastatin and simvastatin 1 day after TBI and daily for 14 days. Morris water maze tests were performed during weeks 2 and 5 after TBI. Bromodeoxyuridine (BrdU; 50 mg/kg) was intraperitoneally injected 1 day after TBI and daily for 14 days. Brain tissue was processed for immunohistochemical staining to identify newly generated cells and vessels. Our data show that (1) treatment of TBI with statins improves spatial learning on days 31-35 after onset of TBI; (2) in the non-neurogenic region of the hippocampal CA3 region, statin treatment reduces the neuronal loss after TBI, demonstrating the neuroprotective effect of statins; (3) in the neurogenic region of the dentate gyrus, treatment of TBI with statins enhances neurogenesis; (4) statin treatment augments TBI-induced angiogenesis; and (5) treatment with simvastatin at the same dose provides a therapeutic effect superior to treatment with atorvastatin. These results suggest that statins may be candidates for treatment of TBI.
创伤性脑损伤(TBI)仍是全球主要的公共卫生问题。目前,尚无恢复TBI所致认知缺陷的方法。在本研究中,我们旨在评估他汀类药物(辛伐他汀和阿托伐他汀)对遭受控制性皮质撞击的大鼠空间学习和神经发生的影响。大鼠在TBI后1天开始用阿托伐他汀和辛伐他汀治疗,持续14天,每日给药。在TBI后第2周和第5周进行莫里斯水迷宫试验。在TBI后1天腹腔注射溴脱氧尿苷(BrdU;50mg/kg),持续14天,每日注射。对脑组织进行免疫组织化学染色,以识别新生成的细胞和血管。我们的数据表明:(1)用他汀类药物治疗TBI可改善TBI发病后第31至35天的空间学习能力;(2)在海马CA3区的非神经源性区域,他汀类药物治疗可减少TBI后的神经元损失, 证明了他汀类药物的神经保护作用;(3)在齿状回的神经源性区域,用他汀类药物治疗TBI可增强神经发生;(4)他汀类药物治疗可增强TBI诱导的血管生成;(5)相同剂量的辛伐他汀治疗比阿托伐他汀治疗具有更好的治疗效果。这些结果表明,他汀类药物可能是治疗TBI的候选药物。